Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar



Article History
Submitted: 09 Jun 2016
Revised: 01 Feb 2017
Accepted: 15 Feb 2017
First published online: 13 Apr 2017

Article Access Statistics
Abstract Page Views: 153
PDF Downloads: 99
Full Text Views: 0

Adv Pharm Bull. 2017;7(1):21-34 doi: 10.15171/apb.2017.004

The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering

Review Article

Abbas Mohajeri 1,2, Sarvin Sanaei 2, Farhad Kiafar 1, Amir Fattahi 3, Majid Khalili 4, Nosratollah Zarghami 2,3,5 *

1 Department of Biotechnology, Zahravi Pharmaceutical Company, Tabriz, Iran.
2 Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Department of Basic Science, Maragheh University of Medical Sciences, Maragheh, Iran.
5 Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences,Tabriz, Iran.

* Corresponding Author: Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences,Tabriz, Iran. E-mail: zarghami@tbzmed.ac.ir



Abstract
Angiogenesis plays an essential role in rapid growing and metastasis of the tumors. Inhibition of angiogenesis is a putative strategy for cancer therapy. Endostatin (Es) is an attractive anti-angiogenesis protein with some clinical application challenges including; short half-life, instability in serum and requirement to high dosage. Therefore, production of recombinant endostatin (rEs) is necessary in large scale. The production of rEs is difficult because of its structural properties and is high-cost. Therefore, this review focused on the different expression systems that involved in rEs production including; mammalian, baculovirus, yeast, and Escherichia coli (E. coli) expression systems. The evaluating of the results of different expression systems declared that none of the mentioned systems can be considered to be generally superior to the other. Meanwhile with considering the advantages and disadvantage of E. coli expression system compared with other systems beside the molecular properties of Es, E. coli expression system can be a preferred expression system for expressing of the Es in large scale. Also, the molecular bioengineering and sustained release formulations that lead to improving of its stability and bioactivity will be discussed. Point mutation (P125A) of Es, addition of RGD moiety or an additional zinc biding site to N-terminal of Es , fusing of Es to anti-HER2 IgG or heavy-chain of IgG, and finally loading of the endostar by PLGA and PEG- PLGA nanoparticles and gold nano-shell particles are the effective bioengineering methods to overcome to clinical changes of endostatin.






Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Mohajeri A
Articles by Sanaei S
Articles by Kiafar F
Articles by Fattahi A
Articles by Khalili M
Articles by Zarghami N

PubMed
Articles by Mohajeri A
Articles by Sanaei S
Articles by Kiafar F
Articles by Fattahi A
Articles by Khalili M
Articles by Zarghami N



Share this article!

Press Manuscript Online. Powered by MAADRAYAN